PARP Inhibitors Center Stage for Ovarian Cancer

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

Drugs known as PARP inhibitors can improve progression-free survival (PFS) in many patients with advanced ovarian cancers.

Go to full article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.